Skip to main content
OpenTrials
Completed

NCT Number: NCT02916355

Role of Interleukin (IL)-1 in Postprandial Fatigue - The Chäschüechli 2 Study

Role of IL-1 in postprandial fatigue - The Chäschüechli 2 Study It is a randomized, single dose, placebo-controlled, double blind, cross-over, proof-of-concept study.

16 healthy young men will be included in this study. The objective of this study is to evaluate if severity of postprandial fatigue is driven by IL-1.

Since fatigue is associated with increased cytokine levels, and since fatigue in chronic inflammatory settings, such as type 2 diabetes, can be reduced by inhibition of IL-1β, postprandial fatigue might also respond to anti-inflammatory intervention with IL-1 inhibition.

The aim of the study is to investigate whether postprandial fatigue is, at least in part, driven by the IL-1 system.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–65 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital Basel, Department of Endocrinology, Diabetes and Metabolism

Basel, CH-4031 Basel, Switzerland

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Male subjects

  • non-smoking
  • apparently healthy
  • BMI >18 and ≤28 kg/m2 or BMI >30 and ≤35 kg/m2
  • Age 20-65 years
  • Subject is usually eating breakfast and lunch
  • Willingness to use contraceptive measures adequate to prevent the subject's partner from becoming pregnant during the study. Adequate contraceptive measures include hormonal methods used for two or more cycles prior to screening (e.g., oral contraceptive pills, contraceptive patch, or contraceptive vaginal ring), double barrier methods (e.g., contraceptive sponge, diaphragm used in conjunction with contraceptive foam or jelly, and condom used in conjunction with contraceptive foam or jelly), intrauterine methods (IUD) and sterilization (e.g., tubal ligation or a monogamous relationship with a vasectomized partner).
  • Owner of a smartphone so they will be able to download and use the sleeping APP, Sleep cycle, prior to the study days.

Exclusion criteria

Subjects will be excluded from the study if they meet any of the following criteria:

  • Night shift workers
  • Subjects suffering from sleep disturbances
  • Clinical signs of infection in the week before inclusion or history of infection during the last 2 months (CRP >5mg/l)
  • Impaired fasting glucose (fasting plasma glucose >5.5mmol/l)
  • Hematologic disease (leukocyte count < 1.5x109/l, hemoglobin <11 g/dl, platelets <100 x 103/ul)
  • Kidney disease (creatinine > 1.5 mg/dl))
  • Liver disease (transaminases >2x upper normal range)
  • Heart disease
  • Pulmonary disease
  • Inflammatory disease
  • History of carcinoma
  • History of tuberculosis
  • Alcohol consumption >40g/d
  • Smoking
  • Known allergy towards Kineret
  • Known allergy to ingredients of the test meal
  • Current treatment with any drug in the week before inclusion, including vitamin supplementation (especially vitamin C and E)
  • Use of any investigational drug within 30 days prior to enrolment or within 5 half-lives of the investigational drug, whichever is longer
  • Subject refusing or unable to give written informed consent

Treatment and study plan

Anakinra

Drug

Subjects will receive Anakinra infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.

Other names: Kineret

NaCl

Drug

subjects will receive NaCl infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.

Other names: sodium chloride

Primary outcomes

  1. The primary outcome is change in fatigue measured by the SSS (Stanford Sleepiness Scale) between groups treated with Anakinra vs. placebo

    Time frame: 7 to 9 days (change between study day 1 and study day 2)

    Fatigue will be measured by using the SSS (Stanford Sleepiness Scale)

Secondary outcomes

  1. Change in postprandial glucose, insulin, C-peptide, glucagon-like Peptide (GLP)-1(active/total), GIP(active/total), PYY, IL-6, tumor necrosis factor (TNF)-alfa, sCRP and cortisol due to any treatment (Anakinra vs. saline).

    Time frame: 7 to 9 days (change between study day 1 and study day 2)

    Blood sampling

  2. Change in heart rate due to any treatment (Anakinra vs. saline)

    Time frame: 7 to 9 days (change between study day 1 and study day 2)

    Pulse watch

  3. Change in insulin due to any treatment (Anakinra vs. saline).

    Time frame: 7 to 9 days (change between study day 1 and study day 2)

    Blood sampling

  4. Change in C-peptide due to any treatment (Anakinra vs. saline).

    Time frame: 7 to 9 days (change between study day 1 and study day 2)

    Blood sampling

  5. Change in GLP-1(active/total) due to any treatment (Anakinra vs. saline).

    Time frame: 7 to 9 days (change between study day 1 and study day 2)

    Blood sampling

  6. Change in GIP(active/total) due to any treatment (Anakinra vs. saline).

    Time frame: 7 to 9 days (change between study day 1 and study day 2)

    Blood sampling

  7. Change in PYY due to any treatment (Anakinra vs. saline).

    Time frame: 7 to 9 days (change between study day 1 and study day 2)

    Blood sampling

  8. Change in IL-6 due to any treatment (Anakinra vs. saline).

    Time frame: 7 to 9 days (change between study day 1 and study day 2)

    Blood sampling

  9. Change in TNF-alfa due to any treatment (Anakinra vs. saline).

    Time frame: 7 to 9 days (change between study day 1 and study day 2)

    Blood sampling

  10. Change in sCRP due to any treatment (Anakinra vs. saline).

    Time frame: 7 to 9 days (change between study day 1 and study day 2)

    Blood sampling

  11. Change in cortisol due to any treatment (Anakinra vs. saline).

    Time frame: 7 to 9 days (change between study day 1 and study day 2)

    Blood sampling

Sponsors and collaborators

Lead sponsor

University Hospital, Basel, Switzerland

Other

Collaborators

  • Rigshospitalet, Denmark

Registry information

Official study title

Role of IL-1 in Postprandial Fatigue - The Chäschüechli 2 Study

Acronym: Chäs2

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Sep 27, 2016
Registry last updated
Jan 29, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.